A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors

Brief description of study

If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer then you have the opportunity to participate in this study. This study has two parts: Part one will look at the tolerability and safety of XMT-1660 (a DAR-6 Dolasynthen-based antibody drug conjugate) in order to determine the maximum tolerated and/or recommended doses of this investigational drug. Part two of this trial will further evaluate the way this drug affects a person's body and how participants respond to the drug with advanced/metastatic cancer.

The study drug XMT-1660 is investigational, the FDA has provided permission to test this agent in the current trial.


Clinical Study Identifier: s22-00389
ClinicalTrials.gov Identifier: NCT05377996
Principal Investigator: Sylvia Adams.
Other Investigators: Yelena Novik, Maryann J Kwa, Marleen I Meyers, Gregory Edward Totero, Caitlin Elizabeth Ryan, Ruth Oratz, Natalie Jill Klar, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.